Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Cameco Corporation is an uranium business based in the US. Cameco Corporation shares (CCJ) are listed on the NYSE and all prices are listed in US Dollars.
|Latest market close||$25.93|
|52-week range||$8.96 - $26.57|
|50-day moving average||$22.15|
|200-day moving average||$19.23|
|Wall St. target price||$25.35|
|Dividend yield||$0.08 (0.32%)|
|Earnings per share (TTM)||$-0.05|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||3.76%|
|1 month (2021-09-24)||29.20%|
|3 months (2021-07-23)||51.81%|
|6 months (2021-04-23)||58.01%|
|1 year (2020-10-23)||166.22%|
|2 years (2019-10-23)||178.22%|
|3 years (2018-10-23)||131.93%|
|5 years (2016-10-21)||222.51%|
Valuing Cameco Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cameco Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cameco Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cameco Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Cameco Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $336.6 million.
The EBITDA is a measure of a Cameco Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.6 billion|
|Operating margin TTM||8.09%|
|Gross profit TTM||$520.1 million|
|Return on assets TTM||1.07%|
|Return on equity TTM||-0.46%|
|Market capitalisation||$9.9 billion|
TTM: trailing 12 months
There are currently 9.4 million Cameco Corporation shares held short by investors – that's known as Cameco Corporation's "short interest". This figure is 2.4% down from 9.6 million last month.
There are a few different ways that this level of interest in shorting Cameco Corporation shares can be evaluated.
Cameco Corporation's "short interest ratio" (SIR) is the quantity of Cameco Corporation shares currently shorted divided by the average quantity of Cameco Corporation shares traded daily (recently around 11.4 million). Cameco Corporation's SIR currently stands at 0.82. In other words for every 100,000 Cameco Corporation shares traded daily on the market, roughly 820 shares are currently held short.
However Cameco Corporation's short interest can also be evaluated against the total number of Cameco Corporation shares, or, against the total number of tradable Cameco Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cameco Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cameco Corporation shares in existence, roughly 20 shares are currently held short) or 0.0236% of the tradable shares (for every 100,000 tradable Cameco Corporation shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cameco Corporation.
Find out more about how you can short Cameco Corporation stock.
We're not expecting Cameco Corporation to pay a dividend over the next 12 months.
Cameco Corporation's shares were split on a 2:1 basis on 22 February 2006. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cameco Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cameco Corporation shares which in turn could have impacted Cameco Corporation's share price.
Over the last 12 months, Cameco Corporation's shares have ranged in value from as little as $8.9554 up to $26.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Cameco Corporation's is 0.8003. This would suggest that Cameco Corporation's shares are less volatile than average (for this exchange).
Cameco Corporation produces and sells uranium. It operates in two segments, Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, and milling, as well as purchase and sale of uranium concentrate. The Fuel Services segment engages in the refining, conversion, and fabrication of uranium concentrate, as well as the purchase and sale of conversion services. This segment also produces fuel bundles or reactor components for CANDU reactors. The company sells its uranium and fuel services to nuclear utilities in the Americas, Europe, and Asia. Cameco Corporation was incorporated in 1987 and is headquartered in Saskatoon, Canada.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.